NASDAQ:VBIV - VBI Vaccines Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.97 0.00 (0.00 %)
(As of 03/22/2019 04:00 PM ET)
Previous Close$1.97
Today's Range$1.9240 - $2.0001
52-Week Range$1.14 - $4.16
Volume182,987 shs
Average Volume342,305 shs
Market Capitalization$192.39 million
P/E RatioN/A
Dividend YieldN/A
Beta1.27
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the target virus. It is also developing congenital cytomegalovirus vaccine candidate for infectious disease; and therapeutic glioblastoma multiforme vaccine candidate for immuno-oncology. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. The company is headquartered in Cambridge, Massachusetts. VBI Vaccines Inc. is a subsidiary of FDS Pharma ASS.

Receive VBIV News and Ratings via Email

Sign-up to receive the latest news and ratings for VBIV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VBIV
CUSIPN/A
Phone617-830-3031

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.36 million
Book Value$1.08 per share

Profitability

Net Income$-63,600,000.00
Net Margins-1,895.74%

Miscellaneous

EmployeesN/A
Market Cap$192.39 million
Next Earnings Date5/7/2019 (Estimated)
OptionableOptionable

VBI Vaccines (NASDAQ:VBIV) Frequently Asked Questions

What is VBI Vaccines' stock symbol?

VBI Vaccines trades on the NASDAQ under the ticker symbol "VBIV."

How were VBI Vaccines' earnings last quarter?

VBI Vaccines Inc (NASDAQ:VBIV) posted its quarterly earnings data on Monday, February, 25th. The biopharmaceutical company reported ($0.28) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by $0.09. VBI Vaccines had a negative net margin of 1,895.74% and a negative return on equity of 68.48%. View VBI Vaccines' Earnings History.

When is VBI Vaccines' next earnings date?

VBI Vaccines is scheduled to release their next quarterly earnings announcement on Tuesday, May 7th 2019. View Earnings Estimates for VBI Vaccines.

What price target have analysts set for VBIV?

3 Wall Street analysts have issued 1 year price objectives for VBI Vaccines' stock. Their predictions range from $9.00 to $12.00. On average, they expect VBI Vaccines' share price to reach $10.50 in the next twelve months. This suggests a possible upside of 433.0% from the stock's current price. View Analyst Price Targets for VBI Vaccines.

What is the consensus analysts' recommendation for VBI Vaccines?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VBI Vaccines in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for VBI Vaccines.

Has VBI Vaccines been receiving favorable news coverage?

News coverage about VBIV stock has been trending neutral on Saturday, InfoTrie reports. The research group scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. VBI Vaccines earned a media sentiment score of 0.2 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days.

Are investors shorting VBI Vaccines?

VBI Vaccines saw a decline in short interest during the month of February. As of February 15th, there was short interest totalling 981,006 shares, a decline of 43.6% from the January 31st total of 1,739,334 shares. Based on an average daily trading volume, of 296,416 shares, the days-to-cover ratio is currently 3.3 days. Approximately 1.3% of the shares of the stock are short sold. View VBI Vaccines' Current Options Chain.

Who are some of VBI Vaccines' key competitors?

What other stocks do shareholders of VBI Vaccines own?

Who are VBI Vaccines' key executives?

VBI Vaccines' management team includes the folowing people:
  • Mr. Jeff R. Baxter, CEO, Pres & Director (Age 58)
  • Dr. David Evander Anderson, Chief Scientific Officer (Age 49)
  • Dr. Francisco Diaz-Mitoma, Chief Medical Officer (Age 64)
  • Mr. Christopher McNulty, CFO & Head of Bus. Devel. (Age 42)
  • Ms. Athena Kartsaklis, Sr. VP of Fin., Chief Compliance Officer & Principal Financial Officer (Age 54)

Who are VBI Vaccines' major shareholders?

VBI Vaccines' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Perceptive Advisors LLC (26.27%), Menora Mivtachim Holdings LTD. (5.77%), General American Investors Co. Inc. (1.94%), Cambridge Investment Research Advisors Inc. (1.48%), Millennium Management LLC (0.83%) and Fosun International Ltd (0.71%). Company insiders that own VBI Vaccines stock include Francisco Diaz-Mitoma, Jeff Baxter, Life Sciences Maste Perceptive, Nell Beattie, Opko Health, Inc, Perceptive Advisors Llc, Steven Gillis and Tomer Kariv. View Institutional Ownership Trends for VBI Vaccines.

Which institutional investors are selling VBI Vaccines stock?

VBIV stock was sold by a variety of institutional investors in the last quarter, including Cambridge Investment Research Advisors Inc.. View Insider Buying and Selling for VBI Vaccines.

Which institutional investors are buying VBI Vaccines stock?

VBIV stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Menora Mivtachim Holdings LTD., General American Investors Co. Inc., Fosun International Ltd, Millennium Management LLC, CVI Holdings LLC, Geode Capital Management LLC and Geode Capital Management LLC. Company insiders that have bought VBI Vaccines stock in the last two years include Francisco Diaz-Mitoma, Jeff Baxter, Life Sciences Maste Perceptive, Nell Beattie, Opko Health, Inc, Perceptive Advisors Llc, Steven Gillis and Tomer Kariv. View Insider Buying and Selling for VBI Vaccines.

How do I buy shares of VBI Vaccines?

Shares of VBIV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is VBI Vaccines' stock price today?

One share of VBIV stock can currently be purchased for approximately $1.97.

How big of a company is VBI Vaccines?

VBI Vaccines has a market capitalization of $192.39 million and generates $3.36 million in revenue each year. The biopharmaceutical company earns $-63,600,000.00 in net income (profit) each year or ($0.97) on an earnings per share basis.

What is VBI Vaccines' official website?

The official website for VBI Vaccines is http://www.vbivaccines.com.

How can I contact VBI Vaccines?

VBI Vaccines' mailing address is 222 Third Street Suite 2241, Cambridge MA, 02142. The biopharmaceutical company can be reached via phone at 617-830-3031 or via email at [email protected]


MarketBeat Community Rating for VBI Vaccines (NASDAQ VBIV)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  232 (Vote Outperform)
Underperform Votes:  179 (Vote Underperform)
Total Votes:  411
MarketBeat's community ratings are surveys of what our community members think about VBI Vaccines and other stocks. Vote "Outperform" if you believe VBIV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VBIV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/23/2019 by MarketBeat.com Staff

Featured Article: Cost of Debt

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel